Antibiotic Use and Misuse in the Neonatal Intensive Care Unit

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 61-68

  Tripathi, Nidhi ^a   Cotten, C Michael ^b   Smith, P Brian ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic; Empiric; Infection; Neonatal intensive care unit; Sepsis

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CORTICOSTEROID DERIVATIVE; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; PENICILLIN G; TOBRAMYCIN; VANCOMYCIN;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AXENIC CULTURE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CANDIDIASIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG CHOICE; DRUG FATALITY; DRUG HYPERSENSITIVITY; EARLY ONSET MENINGITIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INVASIVE CANDIDIASIS; LATE ONSET SEPSIS; MENINGITIS; MULTICENTER STUDY (TOPIC); NECROTIZING ENTEROCOLITIS; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SEPSIS; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; STREPTOCOCCUS AGALACTIAE; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; MICROBIAL SENSITIVITY TESTS; RISK FACTORS; SEPSIS;

EID: 84863406072     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.003     Document Type: Review

References (33)

1. Clark R.H., Bloom B.T., Spitzer A.R., et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006, 117(6):1979-1987.
2. Stoll B.J., Hansen N.I., Adams-Chapman I., et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004, 292(19):2357-2365.
3. Klinger G., Levy I., Sirota L., et al. Outcome of early-onset sepsis in a national cohort of very-low-birth-weight infants. Pediatrics 2010, 125(4):e736-e740.
4. Benjamin D.K., DeLong E., Cotten C.M., et al. Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J Perinatol 2004, 24(3):175-180.
5. Fanaroff A.A., Korones S.B., Wright L.L., et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very-low-birth-weight infants. Pediatr Infect Dis J 1998, 17(7):593-598.
6. Clark R.H., Bloom B.T., Spitzer A.R., et al. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006, 117(1):67-74.
7. Cotten C.M., McDonald S., Stoll B., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely-low-birth-weight infants. Pediatrics 2006, 118(2):717-722.
8. Cotten C.M., Taylor S., Stoll B., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely-low-birth-weight infants. Pediatrics 2009, 123(1):58-66.
9. Cordero L.M., Ayers L.W. Duration of empiric antibiotics for suspected early-onset sepsis in extremely-low-birth-weight infants. Infect Control Hosp Epidemiol 2003, 24(9):662-666.
10. Kuppala V.S., Meinzen-Derr J., Morrow A.L., et al. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011, 159(5):720-725.
11. Stoll B.J., Hansen N.I., Sánchez P.J., et al. Early-onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics 2011, 127(5):817-826.
12. Stoll B.J., Hansen N., Fanaroff A.A., et al. Late-onset sepsis in very-low-birth-weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110(2):285-291.
13. Makhoul I.R., Sujov P., Smolkin T., et al. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very-low-birth-weight infants in Israel: a national survey. Pediatrics 2002, 109(1):34-39.
14. Stoll B.J., Hansen N., Fanaroff A.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347(4):240-247.
15. Hack M., Breslau N., Weissman B., et al. Effect of very low birth weight and subnormal head size on cognitive abilities at school age. N Engl J Med 1991, 325(4):231-237.
16. Muller-Pebody B., Johnson A.P., Heath P.T., et al. Empirical treatment of neonatal sepsis: are the current guidelines adequate?. Arch Dis Child Fetal Neonatal Ed 2011, 96(1):F4-F8.
17. Gupta A., Ampofo K., Rubenstein D., et al. Extended-spectrum lactamase-producing Klebsiella pneumoniae infections: a review of the literature. J Perinatol 2003, 23(6):439-443.
18. de Man P., Verhoeven B., Verbrugh H., et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000, 355(9208):973-978.
19. Bonadio W.A., Hennes H., Smith D., et al. Reliability of observation variables in distinguishing infectious outcome of febrile young infants. Pediatr Infect Dis J 1993, 12(2):111-114.
20. Ottolini M.C., Lundgren K., Mirkinson L.J., et al. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J 2003, 22(5):430-434.
21. Stoll B.J., Hansen N.I., Higgins R.D., et al. Very-low-birth-weight preterm infants with early-onset neonatal sepsis: the predominance of Gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005, 24(7):635-639.
22. Gewolb I., Schwalbe R., Taciak V., et al. Stool microflora in extremely-low-birthweight infants. Arch Dis Child Fetal Neonatal Ed 1999, 80(3):F167.
23. Saiman L., Ludington E., Dawson J.D., et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001, 20(12):1119-1124.
24. Garcia-Prats J.A., Cooper T.R., Schneider V.F., et al. Rapid detection of microorganisms in blood cultures of newborn infants utilizing an automated blood culture system. Pediatrics 2000, 105(3):523-527.
25. Schelonka R.L., Chai M.K., Yoder B.A., et al. Volume of blood required to detect common neonatal pathogens. J Pediatr 1996, 129(2):275-278.
26. Alexander V.N., Northrup V., Bizzarro M.J. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011, 159(3):392-397.
27. Centers for Disease Control and Prevention (CDC) Prevention of perinatal group B streptococcal disease: revised guidelines from the CDC. MMWR Recomm Rep 2002, 51:1-22.
28. Van Dyke M.K., Phares C.R., Lynfield R., et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009, 360(25):2626-2636.
29. Muller A.E., Mouton J.W., Oostvogel P.M., et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother 2010, 54(5):2175-2181.
30. Philipson A., Sabath L.D., Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973, 288(23):1219-1221.
31. Borchardt S., DeBusscher J., Tallman P., et al. Frequency of antimicrobial resistance among invasive and colonizing group B streptococcal isolates. BMC Infect Dis 2006, 6(1):57.
32. Castor M.L., Whitney C.G., Como-Sabetti K., et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008, 2008:727505.
33. Phares C.R., Lynfield R., Farley M.M., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299(17):2056-2065.